Evidence map›Paper›PMID 21508310›Full record

ArticleScience translational medicine2011

The fate and toxicity of Raman-active silica-gold nanoparticles in mice.

Avnesh S Thakor, Richard Luong, Ramasamy Paulmurugan, Frank I Lin, Paul Kempen, Cristina Zavaleta, Pauline Chu, Tarik F Massoud, Robert Sinclair, Sanjiv S Gambhir

Abstract read
In one paragraph

Article in Science translational medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed
17.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 157 citations in OpenAlex.

  1. A Raman-based endoscopic strategy for multiplexed molecular imaging.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Trial
  2. Article
  3. Review
  4. Article
  5. Vascular Disruption Therapy as a New Strategy for Cancer Treatment.International journal of molecular sciences · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Multiplexed imaging in oncology.Nature biomedical engineering · 2022
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Image-guided tumor surgery: The emerging role of nanotechnology.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020
    Review
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Avnesh S ThakorMolecular Imaging Program at Stanford, Department of Radiology, Stanford University, Stanford, CA 94305-5427, USA.
Richard Luong
Ramasamy Paulmurugan
Frank I Lin
Paul Kempen
Cristina Zavaleta
Pauline Chu
Tarik F Massoud
Robert Sinclair
Sanjiv S Gambhir
University of Cambridge · GB

Funding

Stanford Nanocharacterization LaboratoryU54CA119367 · NCI · STANFORD UNIVERSITY · PI GAMBHIR, SANJIV S · 2006 to 2010
$19.8M
Small Animal ImagingP50CA114747 · NCI · STANFORD UNIVERSITY · PI RAO, JIANGHONG · 2005 to 2014
$18.2M
Pilot ProjectsU54CA151459 · NCI · STANFORD UNIVERSITY · PI GAMBHIR, SANJIV S · 2010 to 2014
$12.6M
NCI NIH HHS P50 CA114747NCI NIH HHS U54 CA119367NCI NIH HHS U54 CA151459
6 · The paper itself

Abstract

Raman spectroscopy is an optical imaging method that is based on the Raman effect, the inelastic scattering of a photon when energy is absorbed from light by a surface. Although Raman spectroscopy is widely used for chemical and molecular analysis, its clinical application has been hindered by the inherently weak nature of the Raman effect. Raman-silica-gold-nanoparticles (R-Si-Au-NPs) overcome this limitation by producing larger Raman signals through surface-enhanced Raman scattering. Because we are developing these particles for use as targeted molecular imaging agents, we examined the acute toxicity and biodistribution of core polyethylene glycol (PEG)-ylated R-Si-Au-NPs after different routes of administration in mice. After intravenous administration, PEG-R-Si-Au-NPs were removed from the circulation by macrophages in the liver and spleen (that is, the reticuloendothelial system). At 24 hours, PEG-R-Si-Au-NPs elicited a mild inflammatory response and an increase in oxidative stress in the liver, which subsided by 2 weeks after administration. No evidence of significant toxicity was observed by measuring clinical, histological, biochemical, or cardiovascular parameters for 2 weeks. Because we are designing targeted PEG-R-Si-Au-NPs (for example, PEG-R-Si-Au-NPs labeled with an affibody that binds specifically to the epidermal growth factor receptor) to detect colorectal cancer after administration into the bowel lumen, we tested the toxicity of the core nanoparticle after administration per rectum. We observed no significant bowel or systemic toxicity, and no PEG-R-Si-Au-NPs were detected systemically. Although additional studies are required to investigate the long-term effects of PEG-R-Si-Au-NPs and their toxicity when carrying the targeting moiety, the results presented here support the idea that PEG-R-Si-Au-NPs can be safely used in living subjects, especially when administered rectally.

Indexed as

AnimalsFemaleGoldMaleMetal NanoparticlesMicePolyethylene GlycolsSilicon DioxideSpectrum Analysis, RamanGoldPolyethylene GlycolsSilicon Dioxide

Identifiers

PMID21508310
PMCPMC3873137
OpenAlexW2099459454

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.